International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products

Applying VICH Guidelines : OVERVIEW Focus on stability

Rick Clayton, HealthforAnimals

6th cycle regional seminar for OIE focal ponts for veterinary products Addis Ababa, 9th July 2019





4 CATEGORIES

- > ANALYTICAL VALIDATION
- > <u>IMPURITIES</u>
- > <u>STABILITY</u>
- > <u>SPECIFICATIONS</u>



1. Analytical validation

> Validation of analytical procedures : Definition and Terminology

• VICH GL1 - Implemented in October 1999

> <u>Validation of analytical procedures : Methodology</u>

• VICH GL2 - Implemented in October 1999



2. Impurities

- > Impurities in New Veterinary Drug Substances
 - VICH GL10(R) January 2008
- > Impurities in New Veterinary Medicinal Products
 - VICH GL11(R) –January 2008
- Impurities: Residual Solvents in new veterinary medicinal products, active substances and excipients
 - VICH GL18(R) July 2011





3. Stability


- Stability Testing of New Veterinary Drug Substances and Medicinal Products VICH GL3(R) – January 2008
- > Stability Testing: Requirements for New Dosage Forms
 - VICH GL4 Annex to the VICH GL3 Implemented in May 2000
- > Photostability Testing of New Drug Substances and Products
 - VICH GL5 (Quality Stability) Implemented in May 2000
- > Stability Testing for Medicated Premixes
 - VICH GL8 November 1999
- > Stability testing for biotech/biological products
 - VICH GL 17 July 2001
- > Bracketing and matrixing designs for stability testing
 - VICH GL45 April 2011
- Statistical evaluation of stability data
 - VICH GL51 February 2014n



4. Specifications

- Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances + Decision Trees
 - VICH GL39 November 2006
- > <u>Decision Trees</u>
 - VICH GL39

 VICH GL 40 specifications for biologicals





Stability Guidelines

VICH Stability guidance: objective



What is the objective of VICH stability guidelines?

Provide guidance for conducting the stability studies

of new drug substances or medicinal products that will support a re-test period (drug substance), a shelf life (drug substance/medicinal product) and recommended storage conditions.


Define the stability data package

for a new drug substance or medicinal product that is sufficient for a registration application.

Provide recommendations for the evaluation of stability data

Structure of VICH Stability guidance: Guidance on the stability studies to conduct

> What are the stability guidelines applicable to new drug substances and new medicinal products according to their type?



nalv

ത

DEFINITIONS (1/2)



- New dosage form: a new dosage form is defined as a drug product which is a <u>different pharmaceutical product</u> <u>type</u>, <u>but contains the same active substance</u> as the existing approved product.
- Different pharmaceutical product types include
 - different administration route (e.g., oral to parenteral),
 - new functionality/delivery systems (e.g., immediate release tablet to modified release tablet) and
 - different dosage forms (e.g. capsule to tablet, solution to suspension).



DEFINITIONS (2/2)



Medicated premix (Type A Medicated Article): a medicated premix is a veterinary medicinal product consisting of a mixture of one or more drug substances, generally with a carrier, that is prepared to facilitate oral administration of the drug to animals when mixed with feed.

Biotechnological/biological product (scope of VICH GL17): wellcharacterized proteins and polypeptides, and their derivatives which are isolated from issues, body fluids, cell cultures, or produced using recombinant deoxyribonucleic acid (r-DNA) technology. The guideline does not cover antibiotics, heparins, vitamins, cell metabolites, DNA products, allergenic extracts, conventional vaccines, cells, whole blood, and cellular blood components.

Structure of VICH Stability guidance: <u>General methodology for protocols and data</u>



> Where to find general recommendations for designing the protocol of stability studies and evaluating data?

> VICH guideline GL 5: « Photostability Testing of New Drug Substances and Products"

VICH GL3 (Parent guideline)

«Stability Testing of New Veterinary Drug Substances and Medicinal Products"

General principles for:

x Stress testing

- × Selection of batches
- × Design of stability studies
- x Stability commitments
- × Evaluation of data
- x Statements/Labeling

¤ Testing equipment and protocol

x Stepwise procedure for photostability testing from the API to the packaged drug product

VICH guideline GL 45: «Bracketing and matrixing designs for stability testing of new veterinary drug substances and medicinal products"

× Bracketing: methodology and interpretation of data× Matrixing: methodology and interpretation of data

VICH guideline GL 51: «Statistical evaluation of stability data"


x Recommendations for use of statistical analysis

× Interpretation of stability data in accelerated and intermediate conditions for extrapolation of data at the long-term condition

Access to the guidelines and training material



> VICH website





ABOUT GUIDELINES ACTIVITIES LIBRARY TRAINING CONTACT

Q

N
GENERAL
BIOLOGICALS
PHARMACEUTICALS
PHARMACOVIGILANCE

GUIDELINES

QUALITY

ANALYTICAL VALIDATION | IMPURITIES | STABILITY | SPECIFICATIONS

SAFETY ENVIRONMENTAL SAFETY | METABOLISM AND RESIDUE KINETICS | TOXICOLOGY | TARGET ANIMAL SAFETY | ANTIMICROBIAL SAFETY

EFFICACY GOOD CLINICAL PRACTICE | ANTHELMINTICS | BIOEQUIVALENCE

Analytical validation

- Validation of analytical procedures : Methodology VICH GL2 (Validation methods) – Implemented in October 1999
- Validation of analytical procedures : Definition and Terminology VICH GL1 (Validation definitions) – Implemented in October 1999



TRAINING

VICH

Module 2 - Quality

- VICH Guidelines on Stability: Overview
- VICH GL3 (R) & 4 Stability testing of new veterinary drug substances and medicinal products + Annex GL4 – Requirements for new dosage forms
- <u>VICH GL5</u> Photostability testing of new veterinary drug substances and medicinal products
- VICH GL8 (R) Stability testing for medicated premixes
- <u>VICH GL10</u>: Impurities GL on impurities in new veterinary drug substances
- <u>VICH GL11</u>: Impurities: GL on impurities in new veterinary medicinal products
- <u>VICH GL18 (R)</u>: Impurities: Residual solvents in new veterinary medicinal products, active substance and excipients
- <u>VICH GL45 (R)</u> Bracketing and matrixing designs for stability testing of new veterinary drug substances and medicinal products
- <u>VICH GL51</u> Statistical evaluation of stability data

GENERAL TRAINING MATERIAL

MODULE 1 - GENERAL TOPICS

MODULE 2 - QUALITY

MODULE 3 - EFFICACY

MODULE 4 - SAFETY


MODULE 5 -BIOLOGICALS

MODULE 6 -PHARMACOVIGILANCE



Q

Contact





www.vichsec.org

HEIE HEI